Little Warrior Foundation
Brookfield, WI, 53008, United States
Overview
Little Warrior Foundation accelerates cures for childhood cancer, targeting Ewing's Sarcoma via high-impact research funding.They back life-saving projects and collaborate with partners to boost efficiency and results.Little Warrior Foundation driving breakthroughs in pediatric oncology innovation.
- Total investments
- 1
- Lead investments
- 0
- Investments · 12mo
- 1
- Active investors
- 1
Investment portfolio
- Aptadel Therapeutics
Participated · Equity · Mar 2026
Aptadel Therapeutics, based in the Parque Científico de la Universidad de Barcelona, develops a new generation of RNA‑conjugate molecules (ApDC) aimed at selectively attacking Ewing sarcoma tumor cells. Its lead drug candidate, ADEL‑101, has shown promising activity in cell-based studies and animal models, including tumor localization and antitumor effects. The company plans to use upcoming financing to complete regulatory studies and move into first clinical trials, with a targeted Series A of €9 million in preparation. Financially, Aptadel recently closed a €2 million bridge round with Newsight Tech Angels and Little Warrior Foundation, and received a €450,000 AECC IMPACTO grant in 2025; Little Warrior Foundation had previously invested €480,000. Aptadel positions its technology as potentially reducing side effects and improving efficacy versus current intensive treatments, and intends to expand its platform to reach more pediatric patients.
Team
Piero Spada
LinkedIn